45. Ubrelvy

allergan irvine

Active ingredient: ubrogepant
Disease: migraine
Peak sales estimate: $302 million
Approved: Dec. 23, 2019
Company: Allergan

The scoop: The CGRP migraine prevention field already has three drugs from Amgen, Eli Lilly and Teva vying for market share, and in December, Allergan scored the first approval for an oral CGRP for the acute treatment of migraines. The company plans to launch in early 2020, and market watchers expect the new drug to face competition from Biohaven's rimegepant. In clinical trials, Allergan's drug provided fast pain relief for a majority of patients. It also helped with other symptoms such as nausea, plus light and sound sensitivity. It’s a “much-welcomed development for me and for many who care for patients,” King's College professor and neurologist Peter Goadsby, M.D., said in a statement. EvaluatePharma analysts have predicted the drug will generate $302 million by 2024. — Eric Sagonowsky

45. Ubrelvy

Suggested Articles

With case counts surging and top officials infected, the U.K. is joining the testing for Gilead Sciences' much-hyped antiviral candidate remdesivir.

By redeploying staff, the FDA thinks it can respond to COVID-19-related requests and review protocols within 24 hours of receipt.

The partners leveraged their proximity to the initial outbreak and experience with SARS and MERS to build up a library of neutralizing antibodies.